

STUDIES OF DINUCLEAR AND MONONUCLEAR
COMPLEXES OF INDOMETHACIN:
NEW ANTI-INFLAMMATORY DRUGS

Q. ZHOU

**STUDIES OF DINUCLEAR AND MONONUCLEAR
COMPLEXES OF INDOMETHACIN:
NEW ANTI-INFLAMMATORY DRUGS**

by

Qingdi Zhou

A Thesis Submitted in Fulfillment
of the Requirements for the Degree of
~~Doctor of~~ Philosophy



School of Chemistry, The University of Sydney

Sydney, NSW 2006, Australia

August, 2001

The work presented in this thesis is my own, unless otherwise stated.

Qingdi Zhou

Publications

Journal Papers

Syntheses and Characterization of Anti-Inflammatory Dinuclear and Mononuclear Zinc Indomethacin Complexes. Crystal Structures of $[\text{Zn}_2(\text{Indomethacin})_4(\text{L})_2]$ ($\text{L} = N,N$ -Dimethylacetamide, Pyridine, 1-Methyl-2-pyrrolidinone) and $[\text{Zn}(\text{Indomethacin})_2(\text{L}_1)_2]$ ($\text{L}_1 = \text{Ethanol, Methanol}$)

Zhou, Q.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Turner, P.; Warwick, B.; Biffin J. R.; Regtop, H. L. *Inorg. Chem.* **2000**, 39, 3742-3748.

Metal Complexes of Non-Steroidal Anti-Inflammatory Drugs: An Opportunity Yet to be Realised

Hambley, T. W.; Bonin, A. M.; Davies, N. M.; Dillon, C. T.; Weder, J. E.; Kennedy, B. J.; Lay, P. A.; Morgan, Y. R.; Zhou, Q.; Biffin J. R.; Regtop, H. L.; Warwick, B. *J. Inorg. Biochem.* **2001**, 86, 55.

Micro-SRIXE and Micro-XANES Analysis of Carcinogens and Anti-Inflammatory Drugs in Mammalian Cells

Dillon, C. T.; Davies, N. M.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Zhou, Q.; Stampfl, A. P. J.; Lai, B.; Biffin J. R.; Regtop, H. L. *J. Inorg. Biochem.* **2001**, 86, 203.

Gastrointestinal Damage, Anti-Inflammatory Activity and Superoxide Dismutase Activity of Copper and Zinc Complexes of the Anti-Inflammatory Drug, Indomethacin

Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Zhou, Q.; Davies, N. M.; Biffin J. R.; Regtop, H. L. *J. Bio. Inorg. Chem.* **2001**, submitted.

XAFS Studies of Anti-Inflammatory Dinuclear and Mononuclear Zinc Complexes of Indomethacin

Zhou, Q.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Biffin J. R.; Regtop, H. L. *Inorg. Chem.* **2001**, to be submitted.

Conference Papers

Multiple-Scattering Analysis of the EXAFS and XRD Structures of Solid State of Zinc(II) Indomethacin Complexes

Zhou, Q.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Turner, P. *Royal Australian Chemical Institute 11th National Convention, Inorganic Chemistry Division (Australian National University, Canberra, Australia), 2000, PT30.*

Synthesis, Chemical Characterization and Superoxide Dismutase Activity of Nickel Indomethacin Complexes

Zhou, Q.; Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Biffin J. R.; Regtop, H. L. *Oxidative Pathways in Health and Disease, Incorporating 8th Meeting of the Society for Free Radical Research (Australasia), 30th Meeting of the Australian Society for Experimental Pathology and 32nd Meeting of Australia and New Zealand Environmental Mutagen Society (The University of Sydney, Australia), 1999, 87.*

Investigations of the Biological Properties and SOD Activities of Some Indomethacin-Containing Anti-inflammatory Drugs

Dillon, C. T.; Davies, N. M.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Weder, J. E.; Zhou, Q.; Biffin J. R.; Regtop, H. L. *Oxidative Pathways in Health and Disease, Incorporating 8th Meeting of the Society for Free Radical Research (Australasia), 30th Meeting of the Australian Society for Experimental Pathology and 32nd Meeting of Australia and New Zealand Environmental Mutagen Society (The University of Sydney, Australia), 1999, 15.*

Syntheses, Spectral and Structural Characterization of Two Dinucleating Zinc Complexes [Zn₂(Indomethacin)₄(N,N-Dimethylacetamide)₂] and [Zn₂(Indomethacin)₄(Pyridine)₂]

Zhou, Q.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Turner, P. *Royal Australian Chemical Institute and New Zealand Institute of Chemistry, The Joint Conference of Inorganic Division, IC '99 (Victoria University of Wellington, New Zealand), 1999, M55.*

Studies of the Biochemical Interactions of Copper and Zinc Potential Anti-Inflammatory Drugs

Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Weder, J. E.; Zhou, Q.; Biffin J. R.; Regtop, H. L. *Royal Australian Chemical Institute and New Zealand Institute of Chemistry, The Joint Conference of Inorganic Division, IC '99 (Victoria University of Wellington, New Zealand), 1999, W63.*

Acknowledgments

My best thanks go to my supervisors Dr. Brendan J. Kennedy, Associate Professor Trevor W. Hambley, and Professor Peter A. Lay for giving me patient and enthusiastic guidance, encouragement and support during the completion of my Ph.D. I would also like to acknowledge the receipt of an Australian Postgraduate Research Scholarship Award – Industry (BVR).

I wish to express my appreciation to Drs. Carolyn T. Dillon and Neal M. Davies for their help in the animal assays, and most particular thanks are due to my colleague Carolyn who provided great assistance with the SOD activity assays and performed the statistical analyses. In addition, I am deeply indebted to Dr. Jane E. Weder for her continual willingness to help during the course of my study especially in the X-ray absorption fine structure (XAFS) data analyses. I also thank Drs. Gary J. Foran and James Hester for assistance in the collection of the XAFS data, and Professor Keith Murray for the collection of the variable-temperature magnetic susceptibility data.

Many thanks to Drs. Peter Turner for the X-ray single crystal structural analyses and Ming C. L. Xie for the collection of the 400 MHz NMR data. I am grateful to many people, whose help and suggestions were most valuable throughout the last three years: all my past and present laboratory colleagues, Jean, Prodjo, Rene, Max, Ying, Andrew, Tony, Elizabeth, Leqing, and Service Room staff Fernando and Jeff.

Finally, to my parents, Changtai and Yumin, my husband, Gang, and our two lovely daughters Jade and Helen, for their constant encouragement and patient endurance, I am grateful in measure beyond words.

List of Symbols and Abbreviations

AAS	atomic absorption spectroscopy
BM	Bohr Magneton
BVR	Biochemical Veterinary Research
CMC	carboxymethylcellulose
COX	cyclooxygenase
DMA	<i>N,N</i> -dimethylacetamide
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethylsulfoxide
EPR	electron paramagnetic resonance
e.s.d.	estimated standard deviation
eV	electron Volts
FT	Fourier transform
h	hour(s)
Im	imidazole
IndoH	indomethacin
min	minute(s)
MS	multiple scattering
<i>n</i>	number of rats used in the <i>in vivo</i> assays
N_i	number of independent data points in the XAFS data set
NMP	1-methyl-2-pyrrolidinone
NMR	nuclear magnetic resonance
N_p	number of refinement parameters in the XAFS model
NPBCA	<i>N</i> -pyrimidinobenzamide-2-carboxylic acid
NSAID	non-steroidal anti-inflammatory drug

PBDA	<i>N</i> -phenylbenzamide-2,2'-dicarboxylic acid
PG	prostaglandin
PPD	prescribed daily doses per 1000 of the population
Py	pyridine
R_{as}	distance of the metal absorber atom from the scattering atom
R_{eff}	total distance travelled by the photoelectron; being twice the value of R_{as}
r.m.s	root mean square
R_{xaf}	XAFS model's goodness-of-fit parameter
σ^2	mean square deviation in the distance of the metal absorber atom from the scattering atom
s	second(s)
S_0^2/S	XAFS inelastic loss term/XAFS scale factor
SD	standard deviation
SEM	standard error of mean
SOD	superoxide dismutase
SS	single scattering
μ_{eff}	effective magnetic moment
χ_M	molar magnetic susceptibility
XAS	X-ray absorption spectroscopy
XAFS	X-ray absorption fine structure
XRD	X-ray diffraction

Abstract

Cu(II) complexes of indomethacin (IndoH) have greater efficiency and less GI toxicity in comparison with their parent drug IndoH. This drug was patented in 1994 by Biochemical Veterinary Research (BVR) and is available in Australia in a number of pharmaceutical formulations. Here, the Zn(II), Ni(II) and Co(II) complexes, that have also been patented by BVR, were studied for the chemical and physical properties, efficiencies and GI toxicities.

A number of Zn(II), Ni(II) and Co(II) complexes of Indo were prepared and characterised by various techniques, including single crystal X-ray diffraction and X-ray absorption spectroscopies (XAS). In addition, the superoxide dismutase (SOD) activity, anti-inflammatory property and GI toxicity of the prepared complexes were investigated.

The complexes are unusual in that both monomeric and dimeric complexes are formed and this is the first example of the same carboxylato ligand binding via both carboxylate oxygen atoms in monomeric and dimeric Zn(II) and Ni(II) complexes. The crystal structures of Zn-Indo complexes with *N,N*-dimethylacetamide (DMA), pyridine (Py), 1-methyl-2-pyrrolidinone (NMP), EtOH and MeOH as solvent ligands, $[\text{Zn}_2(\text{Indo})_4\text{L}_2]$ ($\text{L} = \text{DMA}, \text{Py}, \text{NMP}$), *cis*- $[\text{Zn}(\text{Indo})_2\text{L}_2]$ ($\text{L} = \text{EtOH}, \text{MeOH}$), were determined. The three dimeric complexes exhibit dinuclear paddle-wheel structures, as found in the Cu(II) acetate and $[\text{Cu}_2(\text{Indo})_4\text{L}_2]$ ($\text{L} = \text{DMF}, \text{DMSO}, \text{DMA}, \text{EtOH}, \text{CH}_3\text{CN}, \text{Py}$). In these cases, the zinc ions are offset along the *z* direction, such that the $\text{L-Zn}\dots\text{Zn-L}$ moiety is non-linear, unlike the Cu analogues. Each Zn has a square-pyramidal geometry bridged by four carboxylato ligands in the basal plane with the solvent ligands containing an *O*- or *N*-donor atom at the apex. The two monomeric complexes are isostructural and similar in structure to Zn acetate dihydrate. The Zn resides on a two-fold axis and the complexes have a distorted *cis*-octahedral configuration.

The structures of the dimeric and monomeric Ni(II) and Co(II) complexes were confirmed by IR, magnetic properties and X-ray absorption fine structure (XAFS). The dimeric $[\text{Ni}_2(\text{Indo})_4(\text{EtOH})_2]$ complex has a similar structure to that of $[\text{Zn}_2(\text{Indo})_4\text{L}_2]$, whilst the monomeric $[\text{Ni}(\text{Indo})_2(\text{OH}_2)_2]$ and $[\text{Co}(\text{Indo})_2\text{L}_2]$ ($\text{L} = \text{EtOH}, \text{OH}_2$) have a similar *cis*-octahedral geometry as that of $[\text{Zn}(\text{Indo})_2\text{L}_2]$.

The Ni(II) and Co(II) complexes of Indo exhibited significant SOD activities compared with the IndoH in the nitroblue tetrazolium assay. In the acute anti-inflammatory test, the Co(II) chelate was most active followed by the Zn-Indo dimer, Ni(II)-Indo dimer and monomer, and Zn-Indo monomers. Gastric irritancy was markedly reduced by Ni(II) monomer, followed in order by dimeric Ni(II) and Zn(II) complexes. Intestinal damage of the Zn(II), Ni(II) and Co(II) complexes were much less than their parent drug IndoH.

Contents

	<i>Page</i>
Declaration	ii
Publications	iii
Acknowledgements	vi
Contents	vii
List of Tables	xii
List of Figures	xv
List of Symbols and Abbreviations	xxi
Abstract	xxiii

CHAPTER ONE Introduction

1.1	Non-Steroid Anti-Inflammatory Drugs	1
1.2	History of NSAIDs	3
1.3	The Mechanism of NSAIDs	4
1.4	Indomethacin	9
1.5	The Biological Functions of Cu(II), Zn(II), Ni(II) and Co(II)	11
1.5.1	Zinc in Humans and Animals	11
1.5.2	Zinc Absorption and Metabolism	13
1.5.3	Zinc Deficiency and Functions	14
1.5.4	Nickel in Humans and Animals	15
1.5.5	Nickel Absorption and Deficiency	16
1.5.6	Cobalt in Humans and Animals	17
1.5.7	Cobalt Absorption and Vitamin B ₁₂	18
1.5.8	Metal Complexes of Indomethacin and Other NSAIDs	19
1.5.9	The Mode of Action of Metal-NSAID Complexes	22
1.6	Aims and Outline of This Study	23

**CHAPTER TWO Syntheses and Characterisations
of Zinc Indomethacin Complexes.
Crystal Structures of
[Zn₂(Indo)₄L₂] (L = DMA, Py,
NMP) and [Zn(Indo)₂L₂] (L =
EtOH, MeOH)**

2.1	Introduction	35
2.2	Experimental	36
2.2.1	Syntheses	36
2.2.2	Physical Methods	40
2.3	Results	44
2.3.1	Spectroscopic Characterisation	44
2.3.1.1	Infrared Spectroscopy	44
2.3.1.2	NMR Spectroscopy	48
2.3.2	X-ray Powder Diffraction	53
2.3.3	X-ray Crystallography	55
2.4	Discussion	63
2.5	References	65

**CHAPTER THREE XAFS Analyses of Zinc
Complexes of Indomethacin**

3.1	Introduction	69
3.2	Experimental	70
3.2.1	X-ray Absorption Spectra (XAS) Data Collection	70

3.2.2	XAS Data Analyses	71
3.2.2.1	SS XAFS Models	73
3.2.2.2	MS XAFS Models	74
3.3	Results	79
3.3.1	SS XAFS Analyses of Dimeric Zn-Indo Complexes	79
3.3.2	SS XAFS Analyses of Monomeric Zn-Indo Complexes	84
3.3.3	MS Model Fits to the Data of the Zn-Indo Dimers	87
3.3.4	MS Model Fits to the Data of the Zn-Indo Monomers	95
3.4	Discussion	105
3.5	References	108

CHAPTER FOUR Syntheses and Characterisation of Nickel(II) and Cobalt(II) Indomethacin Complexes

4.1	Introduction	110
4.2	Experimental	111
4.2.1	Syntheses	111
4.2.2	Physical Methods	112
4.2.2.1	Spectroscopic Studies and Elemental Microanalyses	112
4.2.2.2	Magnetic Susceptibility	113
4.2.2.3	XAFS Analyses	114
4.3	Results	118
4.3.1	Infrared Spectra	118
4.3.2	Electronic Spectra	120
4.3.3	Magnetic Susceptibility	122
4.3.4	EPR Spectra	125
4.3.5	SS Analyses of XAFS Data	126
4.3.6	MS Analyses of XAFS Data	132
4.4	Discussion	143

CHAPTER FIVE Superoxide Dismutase and Anti-Inflammatory Activities of Zn(II), Ni(II) and Co(II) Complexes of Indomethacin

5.1	Introduction	149
5.2	Experimental	150
5.2.1	SOD Activity Measurement	150
5.2.2	Anti-Inflammatory and Gastrointestinal Test	152
5.3	Results	155
5.3.1	SOD Activity	155
5.3.2	Anti-Inflammatory Activity	158
5.3.3	Acute Macroscopic Gastric Damage	161
5.3.4	Small Intestinal Macroscopic Damage	163
5.3.5	Caecal Haemoglobin Content	164
5.4	Discussion	166
5.5	References	168

CHAPTER SIX Conclusions

171

APPENDICES

Appendix 1	Non-Hydrogen Atomic Coordinates and Parameters for the Single-Crystal XRD for Dimeric and Monomeric Zn-Indo Complexes	173
------------	---	-----

Appendix 2	Selected MS Pathways for Dimeric Zn-Indo Complexes	182
Appendix 3	Selected <i>cis</i> -Model MS Pathways for Monomeric Zn-Indo Complexes	193
Appendix 4	MS Fits to XAFS Data of Dimeric Zn-Indo Complexes	198
Appendix 5	MS Fits to XAFS Data of Monomeric Zn-Indo Complexes	203
Appendix 6	Zn <i>K</i> -Edge SS XAFS and Fourier Transforms (Observed, Calculated and Residual) of Zn-Indo Dimers and Zn-Indo Monomers	209
Appendix 7	Zn <i>K</i> -Edge MS XAFS and Fourier Transforms (Observed, Calculated and Residual) of Zn-Indo Dimers and Zn-Indo Monomers	216
Appendix 8	Selected MS Pathways for Ni(II)-Indo Dimer and Ni(II)-, Co(II)-Indo Monomers	223

List of Tables

	<i>Page</i>
Table 1.1 Some NSAIDs and Their Chemical Structures	5
Table 1.2 Zinc Concentrations ($\mu\text{g/g}$) in Human and Animal Tissues	12
Table 1.3 Nickel Concentrations ($\mu\text{g/g}$) in Human and Animal Tissues	16
Table 1.4 Cobalt Concentrations ($\mu\text{g/g}$) in Human and Sheep Tissues	17
Table 1.5 Some Divalent Metal-NSAID Complexes	20
Table 2.1 Crystal Data and Processing Parameters for [Zn ₂ (Indo) ₄ (DMA) ₂]·2DMA, 1 , [Zn ₂ (Indo) ₄ (Py) ₂]·2H ₂ O, 2a , [Zn ₂ (Indo) ₄ (NMP) ₂], 3 , [Zn(Indo) ₂ (EtOH) ₂], 4 , and [Zn(Indo) ₂ (MeOH) ₂], 5	41
Table 2.2 IR Spectral Data for the Amide and Carboxyl Groups of IndoH and the Zinc Complexes of Indo 1-12	45
Table 2.3 Proton (¹ H) Chemical Shifts in DMSO- <i>d</i> ₆ (ppm) for IndoH and Zn-Indo Complexes	50
Table 2.4 Carbon (¹³ C) Chemical Shifts in DMSO- <i>d</i> ₆ (ppm) for IndoH and Zn-Indo Complexes	51
Table 2.5 Lattice Parameters and Selected Details of Refinements of the Powder Diffraction Patterns of [Zn ₂ (Indo) ₄ L ₂] (L = DMA, Py) and [Zn(Indo) ₂ L ₂] (L = EtOH, OH ₂)	55
Table 2.6 Selected Bond Lengths (Å) and Angles (°) for [Zn ₂ (Indo) ₄ L ₂] (L = DMA, Py, NMP) and [Zn(Indo) ₂ L ₂] (L = EtOH, MeOH)	57
Table 3.1 Restraints and Constraints Used for MS Fitting the XAFS Data for [Zn ₂ (Indo) ₄ L ₂] (L = Py, DMA) Complexes	75
Table 3.2 Restraints and Constraints Used for MS Fitting the XAFS Data for <i>cis</i> -[Zn(Indo) ₂ L ₂] (L = EtOH, MeOH, OH ₂) Complexes and <i>cis</i> -[Zn(OAc) ₂ (OH ₂) ₂]	76
Table 3.3 Bond Distances (Å) and Debye-Waller Factors (σ^2 (Å ²)) for	80